Autolus Therapeutics plc ADR (NASDAQ:AUTL) traded at $4.14 at close of the session on current trade day and made an upward move of 0.73% on its previous day’s price.
Looking at the stock we see that its previous close was $4.11 and the beta (5Y monthly) reads 2.031 with the day’s price range being $4.03 – $4.375. In terms of its 52-week price range, AUTL has a high of $7.45 and a low of $2.21. The company’s stock has gained about 4.81% over that past 30 days.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Autolus Therapeutics plc ADR has a market cap of $1.10 billion and is expected to release its quarterly earnings report in November. Estimates by analysts give the company expected earnings per share (EPS) of -0.21, with the EPS growth for the year raised at -0.82 for current year and -0.82 for next year.
The median projection represents growth adding up to -68.00% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for current year is expected to hit 15.26M, or 798.70% up from figures reported last year.
On the other hand, looking at the outlook for the AUTL stock, short term indicators assign the stock an average of 50% Sell, while medium term indicators assign it an average of 50% Sell.
Based on estimates by 3 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 0 have rated the Autolus Therapeutics plc ADR (AUTL) stock as a Hold, while 3 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note the current price level is 8.75% off its SMA20 and 6.27% from its 50-day simple moving average. The RSI (14) is pointing at 58.99 while the volatility over the past week is 5.47% and jumps to 7.04% over the past one month. The beta value is 2.03, while the average true range (ATR) is currently pointing at 0.24. The average price target for the stock over the next 12 months is $9.5, with the estimates having a low of $8 and a high of $11. These price ends are -93.24% and -165.7% off the current price level respectively, although investors could be excited at the prospect of a -129.47% if the AUTL share price touches on the median price of $9.5.
Coming back to Autolus Therapeutics plc ADR (NASDAQ:AUTL), we note that the average 3-month trading volume was 883.73K, while that of the preceding 10-day period stands at 0.82 million. Current shares outstanding are 266.05 million.
The insiders hold 11.07% of the company’s shares while institutions hold 55.65%. The data shows that short shares as of 2024-09-30, stood at 10.09 million at a short ratio of 14.14. This represents a 512.00 short interest in shares outstanding on 2024-09-30. Shares short fall in September from the previous month at 11.43 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock -35.71% down in year-to-date price movement.
